5 Responses

  1. tmana
    tmana November 4, 2008 at 8:30 am | | Reply

    I learned something else about Januvia… or maybe it’s about Merck employees, or about peer-reviewed journals (it’s hard to tell): Abstracts lie. Last week, I looked at a study about Januvia in BMC Endocrine Disorders… the abstract said that the only side effect the investigators found was an increase in hypoglycemic incidents among patients who were already taking sulfonylurea drugs. This completely disregards the known side effects of Januvia, some of which are even mentioned in TV commercials, and which are discussed in the main article.
    The thing that really ticks me off about this is that many professionals read technical-journal abstracts, but not the complete article — sometimes because they’re short on time, but at least as often because the abstract is freely available, and the subscriptions to view the rest of the article are very expensive.

  2. IceKing02
    IceKing02 November 4, 2008 at 11:02 pm | | Reply


    You and Jenny need to expand your knowledge to what is actually known about diabetes and its treatments. Printing half-truths and misleading patients is as dangerous and costly as ignorance..

    Please read the DREAM, the ADOPT, TRIPOD, PIPOD, DPP studies and the work of DeFronzo related to pioglitazone. I’ve been in the medical field prior to the launch of Rezulin, Avandia and Actos…it has NEVER been advocated to use this class of medications for the “rejuvenation” of beta cell mass. This is an interesting theory for humans that TZDs might influence beta cell survival based upon rat and mouse models, but the pancreas of a rat or mouse is known to be far more plastic than those of humans. The primary action of the TZDs is to break insulin resistance in the periphery as a compliment to the action of metformin. That is how they have always been presented.
    The second place where you are treading in dangerous territory is when commenting upon the role of FDA in drug regulation. The fact that a drug is better than placebo IS a valid comparison. Please understand that it is the mechanism of action of a medication that is just as important as it’s potency in lowering blood sugars. Using the logic that a new drug must be more potent than an old drug would, in fact, mean that the only drug available to treat diabetes is insulin. Every oral agent that came after insulin has been less potent in controlling sugars. Furthermore, if you and Jenny were to understand the difference between treating sugars and treating the core defects of diabetes it would be reflected in your pages. Please work hard to educate your own selves and those whom you serve. We need less ignorance, not more. Please take every comment with humility, I am interested to see everyone involved in diabetes to be more educated and motivated.

    Yours truly,


  3. Is Januvia worth the price? | The eDrugSearch Blog

    [...] Amy at Diabetes Mine points out that Merck has been pushing the drug very hard, and that while it appears to be effective, there are also concerns about safety and side effects. [...]

  4. Ortopeet
    Ortopeet November 2, 2009 at 12:42 am | | Reply

    Please advise on short term memory and Januvia use, I find it difficult to concentrate during the day, taking 100mg Januvia at night after evening meal.

    Also taking 850 Metformin twice daily

    Should I go back to Diamicron?


Leave a Reply